AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21258269 — intervention group
Group type: COMPARATOR
Intervention: Depressive symptoms and drug use before sex
Number of subjects: 717
Study 19681775 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.5 g/kg/day)
Number of subjects: 60
Study 19681775 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 60
Study 19681775 — intervention group
Group type: COMPARATOR
Intervention: Amino acids solution (Control Group)
Number of subjects: 60
Study 17374650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet (approximately 10 servings/d for 2 weeks)
Number of subjects: 63
Study 17374650 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (fruit- and vegetable-free)
Number of subjects: 63
Study 17374650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet (for women with 7/7 genotype)
Number of subjects: 63
Study 15479889 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity weightbearing exercises
Number of subjects: 281
Study 15479889 — intervention group
Group type: COMPARATOR
Intervention: Usual care physical therapy (UC)
Number of subjects: 281
Study 11715159 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine
Number of subjects: 0
Study 11715159 — intervention group
Group type: COMPARATOR
Intervention: No vaccine
Number of subjects: 0
Study 9591170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (40-50% of 1 RM)
Number of subjects: 0
Study 9591170 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (75-85% of 1 RM)
Number of subjects: 0
Study 9591170 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (not specifically defined)
Number of subjects: 0
Study 9591170 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (20 min)
Number of subjects: 0
Study 7605232 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (QG) - i.v. digital + quinidine up to 600 mg
Number of subjects: 60
Study 7605232 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide (PG) - i.v. digital + i.v. procainamide, 10 mg/kg
Number of subjects: 60
Study 7605232 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (AG) - i.v. amiodarone, 5 mg/kg
Number of subjects: 60
Study 3291072 — intervention group
Group type: EXPERIMENTAL
Intervention: Diribiotin CK
Number of subjects: 56
Study 31931532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 341
Study 31931532 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 341
Study 30207488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide after chemotherapy
Number of subjects: 209
Study 30207488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide after chemotherapy in abiraterone-pretreated patients
Number of subjects: 209
Study 30207488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide after chemotherapy in abiraterone-naive patients
Number of subjects: 209
Study 28764752 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated knowledge translation (KT) intervention
Number of subjects: 0
Study 28764752 — intervention group
Group type: COMPARATOR
Intervention: Passive KT intervention
Number of subjects: 0
Study 26261113 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL) sessions on topics of diarrhea, fever of unknown origin, urinary tract infection
Number of subjects: 88
Study 26261113 — intervention group
Group type: COMPARATOR
Intervention: Self-study on the same topics without attending TBL sessions
Number of subjects: 88
Study 26261113 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL) sessions
Number of subjects: 88
Study 23154636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart music
Number of subjects: 55
Study 23154636 — intervention group
Group type: EXPERIMENTAL
Intervention: Dream Theater music
Number of subjects: 55
Study 23154636 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 55
Study 21624142 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth cardiac rehabilitation program delivered via mobile phones and the Internet over six months.
Number of subjects: 170
Study 21624142 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac rehabilitation care.
Number of subjects: 170
Study 18573775 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered decision aid (DA) booklet about outcomes of biennial faecal occult blood testing (FOBT) screening
Number of subjects: 314
Study 18573775 — intervention group
Group type: COMPARATOR
Intervention: Government consumer guidelines (G)
Number of subjects: 314
Study 18573775 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered decision aid (DA)
Number of subjects: 314
Study 17131458 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich fruit juices
Number of subjects: 0
Study 17131458 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol mixtures in vitro
Number of subjects: 0
Study 14701887 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based open access urological investigation service for LUTS
Number of subjects: 959
Study 14701887 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based open access urological investigation service for LUTS and MH
Number of subjects: 959
Study 14701887 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based open access urological investigation service
Number of subjects: 959
Study 10678548 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg once daily (group 1)
Number of subjects: 108
Study 10678548 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 80 mg once daily plus benazepril 5 or 10 mg once daily (group 2)
Number of subjects: 108
Study 10678548 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg once daily plus benazepril 5 or 10 mg once daily (group 3)
Number of subjects: 108
Study 9213834 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxophylline
Number of subjects: 20
Study 9213834 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 20
Study 8066473 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular sauna baths
Number of subjects: 25
Study 8066473 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 25
Study 8066473 — intervention group
Group type: COMPARATOR
Intervention: Heavy exertion
Number of subjects: 25
Study 2686413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 51
Study 2686413 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 51
Study 999485 — intervention group
Group type: EXPERIMENTAL
Intervention: True feedback condition
Number of subjects: 18
Study 999485 — intervention group
Group type: EXPERIMENTAL
Intervention: No feedback condition
Number of subjects: 18
Study 999485 — intervention group
Group type: COMPARATOR
Intervention: Placebo feedback condition
Number of subjects: 18
Study 31241511 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 65
Study 28262253 — intervention group
Group type: EXPERIMENTAL
Intervention: Onstep technique
Number of subjects: 259
Study 28262253 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein technique
Number of subjects: 259
Study 25783468 — intervention group
Group type: COMPARATOR
Intervention: GnRH(AG) + PL
Number of subjects: 70
Study 25783468 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH(AG) + E2
Number of subjects: 70
Study 25783468 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH(AG) + PL + Ex
Number of subjects: 70
Study 25783468 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH(AG) + E2 + Ex
Number of subjects: 70
Study 23912021 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk warmed using water baths (temperature range: 23.3°C to 45.5°C at start, 23.8°C to 38.4°C at removal)
Number of subjects: 33
Study 23912021 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerated breast milk (temperature range: 3.8°C to 27.1°C warmed to 21.8°C to 36.2°C at feeding time)
Number of subjects: 33
Study 21621673 — intervention group
Group type: EXPERIMENTAL
Intervention: 0% BWS
Number of subjects: 12
Study 21621673 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% BWS
Number of subjects: 12
Study 21621673 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% BWS
Number of subjects: 12
Study 19663597 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin 11 mg/kg/day for 14 days (Group A)
Number of subjects: 329
Study 19663597 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin 11 mg/kg/day for 21 days (Group B)
Number of subjects: 329
Study 16728716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ethanol (0.5 g/kg body weight per day)
Number of subjects: 122
Study 16728716 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (15 mug/kg body weight per hour)
Number of subjects: 122
Study 16728716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg four times daily)
Number of subjects: 122
Study 16728716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 15298657 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20-50 mg/day
Number of subjects: 191
Study 15298657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 11736682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg ropivacaine
Number of subjects: 43
Study 11736682 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg ropivacaine
Number of subjects: 43
Study 11736682 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg ropivacaine
Number of subjects: 43
Study 11736682 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-3 mg/kg ropivacaine
Number of subjects: 43
Study 8564629 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms, dry powder inhalation
Number of subjects: 16
Study 8564629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1845606 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef tallow
Number of subjects: 10
Study 1845606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa butter
Number of subjects: 10
Study 1845606 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 10
Study 1845606 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter fat
Number of subjects: 10
Study 6813482 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate (GSTM)
Number of subjects: 112
Study 6813482 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF)
Number of subjects: 112
Study 31208690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moodivate (self-help behavioral activation mobile app)
Number of subjects: 52
Study 31208690 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodKit (active control cognitive-behavioral therapy-based mobile app)
Number of subjects: 52
Study 31208690 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU; no app)
Number of subjects: 52
Study 28668664 — intervention group
Group type: EXPERIMENTAL
Intervention: Paro (companion robot)
Number of subjects: 30
Study 28668664 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 30
Study 26204125 — intervention group
Group type: COMPARATOR
Intervention: Hand Expression (HE)
Number of subjects: 26
Study 26204125 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric Expression (EE)
Number of subjects: 26
Study 23691965 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive sensory innervation to the glabrous skin AVS in FM patients
Number of subjects: 33
Study 23691965 — intervention group
Group type: EXPERIMENTAL
Intervention: SNRI compounds
Number of subjects: 33
Study 23691965 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 33
Study 21496324 — intervention group
Group type: EXPERIMENTAL
Intervention: Geoadditive models assessing spatial variation of HIV infections
Number of subjects: 3469
Study 19140909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide therapy
Number of subjects: 16
Study 17563127 — intervention group
Group type: EXPERIMENTAL
Intervention: COB + enfuvirtide
Number of subjects: 157
Study 17563127 — intervention group
Group type: COMPARATOR
Intervention: COB + PI
Number of subjects: 157
Study 17563127 — intervention group
Group type: COMPARATOR
Intervention: COB + NRTI + PI
Number of subjects: 157
Study 15339848 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (rhAPC)
Number of subjects: 0
Study 11606840 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 257
Study 11606840 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 257
Study 9675564 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valeriante + norethisterone acetate (Group A)
Number of subjects: 14
Study 9675564 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valeriante + promegestone (Group B)
Number of subjects: 14
Study 7925889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari LC nebulizer operated intermittently
Number of subjects: 10
Study 7925889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pari LC nebulizer operated continuously
Number of subjects: 10
Study 7925889 — intervention group
Group type: COMPARATOR
Intervention: Pari LL nebulizer operated intermittently
Number of subjects: 10
Study 2166142 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy
Number of subjects: 0
Study 2166142 — intervention group
Group type: COMPARATOR
Intervention: Vindesine and cisplatin (VP) chemotherapy
Number of subjects: 0
Study 2166142 — intervention group
Group type: EXPERIMENTAL
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 364409 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg per day for 2 months)
Number of subjects: 22
Study 364409 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 22
Study 364409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31983513 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction with sleep extension
Number of subjects: 52
Study 31983513 — intervention group
Group type: COMPARATOR
Intervention: Caloric restriction without sleep extension
Number of subjects: 52
Study 30558476 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training (14% FiO2, 30-min handgrip training, 4 times a week for 4 weeks)
Number of subjects: 9
Study 30558476 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training (30-min handgrip training, 4 times a week for 4 weeks)
Number of subjects: 9
Study 28949973 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone pessaries (100 mg)
Number of subjects: 787
Study 28949973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study 25829298 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 2 μg
Number of subjects: 405
Study 25829298 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg
Number of subjects: 405
Study 25829298 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg
Number of subjects: 405
Study 25829298 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 20 μg
Number of subjects: 405
Study 25829298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 22549084 — intervention group
Group type: EXPERIMENTAL
Intervention: Kettlebell training for 10 weeks, structured in a group setting for 2 days per week.
Number of subjects: 37
Study 20876189 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 strategy (group information and referral for screening)
Number of subjects: 1276
Study 20876189 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 strategy (group information and in situ screening)
Number of subjects: 1276
Study 20876189 — intervention group
Group type: COMPARATOR
Intervention: S0 strategy (no intervention)
Number of subjects: 1276
Study 19884816 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole, clarithromycin, and amoxicillin (PCA) for 14 days
Number of subjects: 98
Study 19884816 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine-bismuth citrate, clarithromycin, and amoxicillin (RCA) for 14 days
Number of subjects: 98
Study 17265148 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of olanzapine
Number of subjects: 8
Study 17265148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15145926 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (≥6 metabolic equivalents) and high calcium intake
Number of subjects: 76
Study 15145926 — intervention group
Group type: COMPARATOR
Intervention: Total physical activity
Number of subjects: 76
Study 11224891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone sodium succinate (MPSS)
Number of subjects: 46
Study 11224891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9148142 — intervention group
Group type: EXPERIMENTAL
Intervention: Encouragement to use condoms for HIV/STD prevention
Number of subjects: 0
Study 8220058 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva test pipeline procedure
Number of subjects: 1582
Study 8220058 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1582
Study 3085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitradisc 32 mg patch
Number of subjects: 24
Study 3085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Transiderm‐Nitro 50 mg patch
Number of subjects: 24
Study 3085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitro-Dur 104 mg patch
Number of subjects: 24
Study 3085698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrobid 2% ointment
Number of subjects: 24
Study 29732536 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment of Insomnia (CBTi)
Number of subjects: 0
Study 29732536 — intervention group
Group type: COMPARATOR
Intervention: Sham control intervention
Number of subjects: 0
Study 27222436 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation (tVNS) during the extinction phase
Number of subjects: 31
Study 27222436 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during the extinction phase
Number of subjects: 31
Study 24513113 — intervention group
Group type: COMPARATOR
Intervention: 0F-200 (no fluoride in 200 ml milk)
Number of subjects: 28
Study 24513113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5F-100 (1.5 mg fluoride in 100 ml milk)
Number of subjects: 28
Study 24513113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F-100 (3 mg fluoride in 100 ml milk)
Number of subjects: 28
Study 24513113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5F-200 (1.5 mg fluoride in 200 ml milk)
Number of subjects: 28
Study 24513113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F-200 (3 mg fluoride in 200 ml milk)
Number of subjects: 28
Study 24513113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5F-200
Number of subjects: 28
Study 24513113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride in 100 ml milk
Number of subjects: 28
Study 24513113 — intervention group
Group type: EXPERIMENTAL
Intervention: All fluoridated milk treatments
Number of subjects: 28
Study 22934395 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of autologous blood (2 mL/acupoint, once a week for 4 weeks)
Number of subjects: 42
Study 22934395 — intervention group
Group type: COMPARATOR
Intervention: Motilium (10 mg, 3 times daily for 4 weeks)
Number of subjects: 42
Study 22934395 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of autologous blood
Number of subjects: 42
Study 22934395 — intervention group
Group type: COMPARATOR
Intervention: Motilium
Number of subjects: 42
Study 19577251 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 93
Study 19577251 — intervention group
Group type: COMPARATOR
Intervention: T-tube insertion
Number of subjects: 93
Study 17599483 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycemic control protocol (insulin administration)
Number of subjects: 300
Study 17599483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no protocol)
Number of subjects: 300
Study 15595583 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia with bupivacaine 0.25%
Number of subjects: 59
Study 15595583 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia with bupivacaine 0.25% and sufentanil 0.001 mg/mL
Number of subjects: 59
Study 11757212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone (bolus of 70 to 140 mg)
Number of subjects: 200
Study 11757212 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propafenone (300 to 600 mg)
Number of subjects: 200
Study 9702292 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid carcinoma
Number of subjects: 48
Study 9702292 — intervention group
Group type: COMPARATOR
Intervention: Adenomas and surrounding tissue
Number of subjects: 48
Study 9702292 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcinomas
Number of subjects: 48
Study 9702292 — intervention group
Group type: EXPERIMENTAL
Intervention: Medullary and papillary-follicular carcinoma
Number of subjects: 48
Study 9702292 — intervention group
Group type: COMPARATOR
Intervention: Adenomas and surrounding tissues
Number of subjects: 48
Study 8059021 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (V) 80 mg/8 h per os before surgery and 5 mg/4-6 h slow infusion during the next intra- and postoperative 24-36 h
Number of subjects: 35
Study 8059021 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 35
Study 10303912 — intervention group
Group type: EXPERIMENTAL
Intervention: EC/IC bypass grafting
Number of subjects: 1377
Study 10303912 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1377
Study 6313597 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of acyclovir (400 to 1200 mg/m2/dose)
Number of subjects: 21
Study 6313597 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acyclovir and human alpha interferon (2 to 40 X 10(4) units/kg/day)
Number of subjects: 21
Study 6313597 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 21